Leadership Turmoil at the FDA: What the Makary Departure Means for Pharma

May 9, 2026 - President Donald Trump has reportedly signed off on a plan to dismiss FDA Commissioner Marty Makary, according to multiple media reports. The potential departure, coming just 14 months into Makary's tenure, adds another layer of uncertainty to an agency already operating with acting heads in its top drug development departments - and has immediate implications for pharmaceutical companies, CDMOs, and API suppliers.

The news sent ripples through the biopharma sector. Replimune, a biotech whose oncolytic virus therapy application had been twice rejected by the FDA under Makary, saw its stock surge nearly 22%. BMO analysts characterized the potential change as "positive for biopharma," with markets expecting any successor to prioritize stability and predictability.

A Tenure Marked by Controversy

Makary, a surgical oncologist from Johns Hopkins, was confirmed as FDA commissioner in March 2025. His tenure became closely associated with the Make America Healthy Again (MAHA) movement. Key controversial positions included pushing for large placebo-controlled vaccine trials in lower-risk age groups, inconsistent review standards for rare-disease drugs, and increasing political entanglement in regulatory decisions. Upon his potential departure, the FDA would be left without a permanent commissioner while already operating with acting heads in its top drug development departments.

Impact on Drug Approval Timelines

For pharmaceutical companies and their supply chain partners, leadership transitions at the FDA create tangible operational challenges:

Near-Term Uncertainty:

• Pending drug applications may experience delays as new leadership establishes priorities
• Review team assignments and decision-making processes may shift during transition periods
• Pre-approval manufacturing inspections could face scheduling disruptions

Strategic Repositioning:

• Companies with applications in late-stage review may need to recalibrate launch timelines
• CDMOs and API suppliers serving companies with pending approvals face schedule adjustments
• Regulatory strategy consultants may see increased demand for adaptive planning

Implications for API and CDMO Suppliers

The FDA leadership transition has specific implications for B2B pharmaceutical suppliers:

Regulatory Inspection Cadence:

• Pre-approval inspections (PAIs) for new drug applications may be delayed or rescheduled
• Routine GMP inspection frequency could shift depending on new leadership priorities
• Foreign manufacturing facility inspections may face reprioritization

DMF and ANDA Processing:

• Drug Master File (DMF) reviews may experience processing delays
• Abbreviated New Drug Application (ANDA) approvals could slow during transition
• Cross-referencing DMFs for pending applications may face uncertainty

The Broader Pattern: FDA Leadership Instability

The Makary situation is part of a broader pattern of leadership instability across U.S. health agencies. This instability creates compounding challenges including institutional memory loss, policy inconsistency, potential impact on international competitiveness, and staff retention concerns among experienced reviewers and inspectors.

Strategic Recommendations for B2B Suppliers

Pharmaceutical suppliers should consider the following actions:

• Diversify regulatory exposure: Pursue approvals in multiple jurisdictions to reduce dependence on U.S. FDA timelines
• Strengthen compliance posture: Maintain robust GMP compliance to minimize inspection-related risks during transitions
• Monitor policy signals: Track early appointments and statements from new FDA leadership for directional cues
• Build flexibility into timelines: Buffer project schedules against potential regulatory delays
• Engage industry associations: Participate in trade groups advocating for regulatory stability

Outlook

The FDA's next commissioner will inherit an agency at a crossroads: balancing political pressures with scientific rigor, managing a backlog of pending applications, and maintaining the United States' position as a global leader in pharmaceutical innovation. For API and intermediate suppliers, the transition period represents both risk and opportunity. Companies that maintain regulatory excellence and build adaptive capacity will be best positioned to navigate the uncertainty. The key message for the B2B pharmaceutical supply chain: prepare for short-term disruption, but remain focused on long-term quality and compliance fundamentals that transcend any single administration's priorities.